UNITED STATES SECURITIES AND EXCHANGE COMMISSION or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38266 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ( State or other jurisdiction of inco ...

Spero Therapeutics Announces Second Quarter 2021 Operating Results and Provides Business Update August 5, 2021 Tebipenem HBr on track for NDA submission in the fourth quarter of 2021 Announced $40 million equity investment from Pfizer Inc. and licensing agreement for SPR206 Initiated Phase 1 bronchoalveolar lavage and renal impairment clinical trials of SPR206 Conference call and live webcast at 4:30 p.m. ET today CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a ...

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2021 Earnings Conference Call August 5, 2021 4:30 PM ET Company Participants Ted Jenkins - VP, IR Ankit Mahadevia - Co-Founder, CEO, President & Director David Melnick - Chief Medical Officer Cristina Larkin - COO Satyavrat Shukla - CFO Conference Call Participants Lyla Youssef - Cowen and Company Louise Chen - Cantor Fitzgerald & Co. Kevin DeGeeter - Oppenheimer Esther Hong - Berenberg Raghuram Selvaraju - H.C. Wainwright & Co. Operator Good day, everyone, and than ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38266 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) ( State or other jurisdiction of incorpora ...

Ladenburg Thalmann Healthcare Conference July 13, 2021 Forward-looking Statements 2 This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, the design, initiation, timing and submission to the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA) for tebipenem HBr and the potential approval of tebipenem HBr by the FDA; future commercialization, the potential number of patients who could be treat ...

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q1 2021 Earnings Conference Call May 6, 2021 4:30 PM ET Company Participants Ashley Robinson - Investor Relations Ankit Mahadevia - Chief Executive Officer David Melnick - Chief Medical Officer Cristina Larkin - Chief Operating Officer Sath Shukla - Chief Financial Officer Conference Call Participants Ritu Baral - Cowen Louise Chen - Cantor Fitzgerald Kevin DeGeeter - Oppenheimer Esther Hong - Berenberg Ram Selvaraju - H.C. Wainwright Operator Greetings and welcome to ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38266 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) ( State or other jurisdiction of incorpor ...

Corporate Presentation Oppenheimer Healthcare Conference March 16, 2021 Forward-looking Statements 2 This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, the design, initiation, timing and submission to the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA) for tebipenem HBr and the potential approval of tebipenem HBr by the FDA; future commercialization, the potential number of patients w ...

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2020 Earnings Conference Call March 11, 2021 4:30 PM ET Company Participants Sharon Klahre – Vice President of Investor Relations and Strategic Finance Ankit Mahadevia – Chief Executive Officer David Melnick – Chief Medical Officer Cristina Larkin – Chief Operating Officer Sath Shukla – Chief Financial Officer Conference Call Participants Lyla Youssef – Cowen & Company Louise Chen – Cantor Fitzgerald Kevin DeGeeter – Oppenheimer Esther Hong – Berenberg Ram Selvaraju ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____to____ Commission file number 001-38266 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) | Delaware | 46-4590683 | | --- | --- | ...